FDA clears Keytruda/Padcev regimen for bladder cancer

The combination of Merck & Co’s checkpoint inhibitor Keytruda and Seagen/Astellas’ antibody-drug conjugate Padcev has been approved by the FDA as an alternative to che

Forget Merck, now Pfizer is said to be after Seagen

Rumour of negotiations comes as Pfizer is facing a steep patent cliff in the next few years.

Trial win sets up new use for Astellas, Seagen's Padcev in b...

Astellas and Seagen's Padcev is on course to move further up the treatment pathway in bladder cancer, thanks to a positive readout in the EV-103 clinical trial.

Astellas, Seagen seek speedy reviews of Padcev in bladder ca...

The next milestone in Seagen and Astellas' bid to build their antibody-drug conjugate (ADC) Padcev into a blockbuster will come in August, when the FDA concludes an accelerated review of tw

Astellas/Seagen prepare full US filing of bladder cancer dru...

Astellas and Seagen have the data they need for a full licence for their bladder cancer drug Padcev in the US, based on trial results announced over the weekend.

Seattle Genetics says data backs Padcev combo for first-line...